Edesa Biotech, Inc.
EDSA evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $40.8M
- Lead Asset:
- eb05 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for EDSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EDSA
Edesa Biotech, Inc. (EDSA) is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, with a pipeline focused on medical dermatology and respiratory indications.
Key risk: Early-stage pipeline
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$40.8M
Cash Runway
—
Lead Asset
eb05 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Edesa Biotech, Inc..
Edesa Biotech, Inc. (EDSA) is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, with a pipeline focused on medical dermatology and respiratory indications.
- Cash & equivalents of $10.3M as of 2026-06-30 [sec].
- Net loss of -$5.4M for the nine months ended June 30, 2026 [sec].
- Shareholders' equity of $8.8M as of 2026-06-30 [sec].
- Lead dermatology candidate EB06 (anti-CXCL10 monoclonal antibody) is preparing for a Phase 2 study in vitiligo [sec_mda · as of 2026-08-13].
- Paridiprubart (EB05) demonstrated positive exploratory data in acute kidney injury (AKI) and a statistically significant reduction in 28-day mortality in a Phase 3 ARDS study [news · published 2026-07-02][sec · filed 2026-07-02].
What works
- Paridiprubart (EB05) showed a statistically significant reduction in 28-day mortality across a 278-patient Phase 3 ARDS study, with consistent benefits across severity groups [sec · filed 2026-07-02].
- EB06 has demonstrated a favorable safety and tolerability profile to date and has received regulatory approval from Health Canada for a Phase 2 study [sec · filed 2026-07-02].
- The company has a cash position of $10.3M as of 2026-06-30, providing near-term operational runway [sec].
What to weigh
- The company reported a net loss of -$5.4M for the nine months ended June 30, 2026, indicating ongoing cash burn [sec].
- EB06 is still in early-stage development (Phase 2 preparation) and has not yet generated pivotal efficacy data [sec_mda · as of 2026-08-13].
- Paridiprubart's Phase 3 ARDS study was truncated, and the competitive landscape for its COVID-19 indication includes over 100 competitors [pipeline].
- The company plans to commit substantial resources to R&D and clinical trials, which could materially affect liquidity and may require additional debt or equity financing [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Paridiprubart reduced 28-day mortality in a Phase 3 ARDS study.
“paridiprubart demonstrated a statistically significant reduction in 28-day mortality”
SEC filings · July 2, 2026
EB06 has Health Canada approval for a Phase 2 vitiligo study.
“We have received regulatory approval from Health Canada to conduct a Phase 2”
SEC MD&A · July 2, 2026
Risks & what to watch (4)›
Key risks
- Early-stage pipeline — EB06 is in Phase 2 preparation with no pivotal efficacy data yet [sec_mda · as of 2026-08-13].
- Cash burn and net loss — Net loss of -$5.4M for nine months ended June 30, 2026; cash of $10.3M may fund limited runway [sec].
- Competitive pressure on paridiprubart — Over 100 competitors in the COVID-19 indication for paridiprubart [pipeline].
- Reliance on strategic transactions — Future growth may require additional debt or equity, impacting liquidity [sec_mda · as of 2026-08-13].
What to watch
- Initiation and enrollment of the Phase 2 EB06 vitiligo study, planned for mid-2026 [news · published 2026-03-26].
- Further data or regulatory updates on paridiprubart in AKI or ARDS [news · published 2026-07-02].
- Cash runway and any new financing or partnership announcements given the net loss and $10.3M cash position [sec].
- Potential strategic transactions or in-licensing of additional assets [sec_mda · as of 2026-08-13].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Edesa Biotech, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Edesa Biotech, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.44
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$13.7M
| Holder | Shares | Value |
|---|---|---|
| velan capital investment management lp | 827,500 | $4.3M |
| rubric capital management lp | 687,500 | $3.6M |
| perceptive advisors llc | 563,239 | $2.9M |
| jane street group, llc | 115,721 | $605K |
| vanguard capital management llc | 85,966 | $450K |
| geode capital management, llc | 77,054 | $403K |
| vanguard fiduciary trust co | 38,446 | $201K |
| state street corp | 37,979 | $199K |
| commonwealth equity services, llc | 35,003 | $183K |
| scientech research llc | 30,534 | $160K |
Showing top 10 of 28 institutional holders of Edesa Biotech, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 4.8%
- Days to cover
- 0.1
- Shares short
- 396,830
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EDSA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Edesa Biotech, Inc.?
Edesa Biotech, Inc. (EDSA) is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, with a pipeline focused on medical dermatology and respiratory indications.
What is Edesa Biotech, Inc.'s lead drug candidate?
Edesa Biotech, Inc.'s most advanced tracked candidate is eb05 (Phase 3) for COVID-19.
Who is the CEO of Edesa Biotech, Inc.?
Dr. Pardeep Nijhawan FRCPC, M.D. is the chief executive officer of Edesa Biotech, Inc. (EDSA).
Where is Edesa Biotech, Inc. headquartered?
Edesa Biotech, Inc. (EDSA) is headquartered in Markham, ON, Canada.
What therapeutic areas does Edesa Biotech, Inc. focus on?
Edesa Biotech, Inc. develops therapies across Oncology, Immunology, Infectious Disease, Respiratory, Dermatology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.